Commentary: UK’s approval of the Oxford-AstraZeneca could be seriously helpful

Commentary: UK’s approval of the Oxford-AstraZeneca could be seriously helpful

January 1, 2021 0 By boss


SOUTHAMPTON: The UK has become the first country to authorise the Oxford-AstraZeneca COVID-19 vaccine for public use, with roll-out to start in the first week of 2021.

This vaccine is the second to be authorised in the UK – following the Pfizer vaccine.

The British government has ordered 100 million doses of the Oxford vaccine, enough to vaccinate 50 million people. Other countries will be watching closely.

Australia has ordered over 50 million doses, Canada 20 million, and worldwide over 2.5 billion doses have been preordered. AstraZeneca expects to be able to supply large numbers of doses within the first quarter of 2021.

READ: Commentary: COVID-19 brought out the best in us. But we paid too steep a price to figure it out

READ: Commentary: Even as vaccines are rolled out, life in 2021 unlikely to return to new normal

Notably, British people will receive two full doses of the vaccine, which in trials prevented people from falling ill with COVID-19 62 per cent of the time.

This is despite trials initially suggesting that an alternative dosing strategy – using half a dose followed by a full dose – could be much more effective, preventing illness with 90 per cent efficacy.

PFIZER’S VACCINE POSES HUGE LOGISTICAL CHALLENGES

The least merry Christmas in recent memory has at least had the silver lining of a highly effective vaccine – Pfizer’s – being available and licensed for use in the UK.

But despite the brilliance of this magic bullet, there are limiting factors – particularly around the scale of production required to meet demand.

READ: Addressing any concerns may persuade more people to get COVID-19 vaccination: Experts

FILE PHOTO: A woman holds a small bottle labeled with a 'Coronavirus COVID-19 Vaccine' st

FILE PHOTO: A woman holds a small bottle labeled with a “Coronavirus COVID-19 Vaccine” sticker and a medical syringe in front of displayed Pfizer logo in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo

The multi-country demand for the Pfizer vaccine is akin to a highly intense hour where the local supermarket has just released some new delivery slots during lockdown, and you’re racing to get the order booked before any of your neighbours notice.

Everyone wants to get in first to ensure delivery of that last pack of toilet roll – or in this case, that next batch of vaccines.

The difficult logistics of storing and transporting the Pfizer vaccine at ultra-low temperatures are also restricting the speed of the national vaccine roll-out.

So we need multiple vaccine candidates to get anywhere near meeting demand, and we need them fast.

Having the Oxford vaccine available could be seriously helpful for accelerating coverage – particularly as in the UK, priority has shifted to getting a first vaccine dose to as many people as possible.

However, there are still gaps in our knowledge, for example around the effectiveness of this vaccine in the elderly, and also whether leaving a longer gap between the doses increases overall effectiveness, as has been suggested.

READ: Commentary: Phase 3 will bring us much-needed closure to a difficult year

READ: Commentary: Our muted joy over Phase 3 is the true new normal

EASIER TO TRANSPORT BUT DIFFERING LEVELS OF EFFECTIVENESS

The three leading vaccines all deliver part of the coronavirus’s genetic material into the body’s cells, leading the cells to produce copies of part of the virus – the spike protein – that the body can then mount an immune response against.

The Oxford vaccine makes this delivery using an adenovirus vector, whereas vaccines from Pfizer and Moderna use an mRNA platform.

Data published previously indicated an overall efficacy of 62 per cent if two doses of the Oxford vaccine are given, which is lower than the 94 per cent of Moderna’s vaccine and 95 per cent of Pfizer’s.

But it was thought that administering a small dose first up and then a full second dose could be more effective. Using this dosing strategy, limited data from the phase 3 trial indicated an efficacy in younger populations of around 90 per cent.

However, the UK Medicines and Healthcare Products Regulatory Agency has said the results of this half-dose full-dose regimen were “not borne out by full analysis” when it conducted its review, so further investigation of this regimen will be needed.

FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London

FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014. REUTERS/Stefan Wermuth/File Photo

But the UK’s Commission on Human Medicines is now suggesting that one dose gives 70 per cent protection after 21 days, and that a second dose potentially increases effectiveness to around 80 per cent – but that the second dose needs to be given 12 weeks after the first.

However, the data showing this has yet to be released.

As has been documented, the Oxford vaccine only needs to be kept at a chilled temperature, whereas Pfizer’s requires -75 degrees Celsius storage and Moderna’s to be kept at around -20 degrees Celsius.

This would make it easier for all countries to manage and distribute, but particularly for low- and middle-income nations.

READ: Commentary: Here’s why taking the vaccine is necessary even if it’s optional

READ: Commentary: A vaccine is on the horizon. But most Singaporeans are adopting a wait-and-see attitude

Across sub-Saharan Africa or South-east Asia, healthcare colleagues are very adept at taking vaccines to hard-to-reach populations but simply don’t have existing infrastructure to ensure ultra-low temperatures can be maintained.

MAY BE ROLLED OUT IN LOW- AND MIDDLE-INCOME COUNTRIES

At US$2 to US$3 per shot, the cost per dose of the Oxford vaccine is much cheaper than the other leading vaccines, making it a potential long-term option for governments when the world is past the point of spending whatever it takes to get the coronavirus under control. Global orders for this vaccine far outstrip those for the others.

The Oxford vaccine is being manufactured in Europe and also in large numbers in India, and is part of the COVAX initiative – led by Gavi, the Vaccine Alliance – so it may be the first western-developed vaccine that is rolled out in large numbers in low- and middle-income countries at some point in 2021.

However, it will be interesting to see how vaccines developed by Russia and China are distributed internationally. China has provided huge amounts of investment for healthcare assistance across the African continent, with the balance of altruism or opportunism being unclear.

A nurse shows a Covid-19 vaccine produced by Chinese company Sinovac Biotech at the Sao Lucas

A nurse shows a Covid-19 vaccine produced by Chinese company Sinovac Biotech at the Sao Lucas Hospital, in Porto Alegre, Brazil AFP/SILVIO AVILA

While we’d love to see this global public health problem treated purely as a public health problem, we may well see vaccines being used as capital to develop new or reaffirm existing political relationships.

Certain vaccines may be favoured ahead of others in some parts of the world due to political influence.

Global vaccine roll-out will be incredibly complex, with a variety of factors inevitably contributing to the extent of its success.

To know the impact of the Oxford vaccine, we’ll have to wait and see.

However, amid the intense doom and gloom of 2020, having multiple effective vaccine candidates available bodes well for 2021.

Listen to infectious disease expert outline what’s needed to get a vaccine manufactured, transported and administered in our Heart of the Matter podcast: 

 

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram​​​​​​

Michael Head is Senior Research Fellow in Global Health, University of Southampton. This commentary first appeared in The Conversation.



Source link